Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital in connection with the acquisition of PointSharp AB
Mandate

Vinge advises Main Capital in connection with the acquisition of PointSharp AB

November 13, 2020 Employment and Benefits Commercial Agreements M&A IT, Telecommunications and Outsourcing Intellectual Property

PointSharp provides security solutions which enable enterprises to secure the login of their users to all their applications through e.g. multi-factor authentication, with a simplified user experience. PointSharp serves more than 220 customers globally.

Vinge’s team consisted of Filip Öhrner, Kristina Ekberg, Jesper Lindvall (M&A), Ebba Svenburg (Employment), Karl-Hugo Engdahl, Carla Zachariasson (Agreements and GDPR/IT), Arvid Axelryd (IPR) and Carl Bruneheim (VDR Assistant).

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025